AF
ALLO icon

Amalgamated Financial’s Allogene Therapeutics ALLO Stock Holding History

Amalgamated Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$85K Buy
+9,350
New +$97.4K ﹤0.01% 2206

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Amalgamated Financial's ALLO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Allogene Therapeutics (ALLO) in Q1 2022: 9,350 shares worth $85K. The stake represents ﹤0.01% of the portfolio and ranks #2206 among its holdings.

180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Amalgamated Financial held 9,350 shares of Allogene Therapeutics worth $85K as of Q1 2022.
  • Allogene Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Allogene Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2206 holding.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.